Biolipox Interim Report, January – June 2007

• Revenues for the period amounted to SEK 15.6 million (22.0). For the second quarter revenues amounted to SEK 7.9 million (11.0).
• Earnings after tax for the period amounted to SEK -57.0 million (-33.5). For the second quarter earnings after tax amounted to SEK -29.4 million (-16.7).
• Earnings per share for the period was SEK -75.31 (-49.69). For the second quarter earnings per share was SEK -38.50 (-24.72).
• Cash flow for the period was negative and amounted to SEK -43.8 million (positive: 3.6). For the second quarter cash flow was negative and amounted to SEK -22.3 million (-13.4).
• Continuous progress in the research and drug development portfolio.
• Commencing pre-clinical trials in eoxin-project to start Phase I study in 2008